|
Ä¿¸®¾îÄɾî |
±¹³» Á¦¾à±â¾÷ RA ¾à»ç (°æ·Â 2³â ÀÌ»ó)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
12.12 |
|
|
´õÀ⽺ |
¾à»çÀڰݺ¸À¯ÇÑ ÀÓ¿ø±Þ °øÀåÀå(Á¦¾à,°Ç°½ÄÇ°)ä¿ë
ÃæºÏ Á¦Ãµ½Ã | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
14³â¡è |
ä¿ë½Ã |
12.01 |
|
|
(ÁÖ)ÅõºñÆÄÆ®³ÊÁî |
°ü¸®¾à»ç(Á¦Á¶/Ç°Áú)
°æ±â ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
ä¿ë½Ã |
11.22 |
|
|
ÄÉÀ̸ÇÆÄ¿ö |
[»óÀå Á¦¾à»ç] ½ÅÁ¦Ç° °³¹ß ÇØ¿Ü ¶óÀ̼¾½ºÀÎ ÃʺùÇÕ´Ï´Ù .
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
10³â¡è |
ä¿ë½Ã |
03.01 |
|
|
ÄÉÀ̸ÇÆÄ¿ö |
[»óÀå Á¦¾à»ç] RA(Regulatory Affairs) ¹× ´ë°ü °ü¸®ÀÚ Ãʺù
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
10³â¡è |
ä¿ë½Ã |
03.01 |
|
|
¹Ý¼®½áÄ¡(ÁÖ) |
¾à»ç ¹× Á¦Á¦¿¬±¸ÆÀÀå ¸ðÁý
Ãæ³² ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
3³â¡è |
»ó½Ãä¿ë |
10.03 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
phamacovigilance Specialist
Ãæ³² õ¾È½Ã, ¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
°æ·Â¹«°ü |
ä¿ë½Ã |
04.04 |
|
|
Ä¿¸®¾îÄɾî |
±Û·Î¹ú Á¦¾àȸ»ç Sr. RA Associate_°æ·Â4³â ÀÌ»ó
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
4³â¡è |
ä¿ë½Ã |
05.09 |
|
|
ÆÄÀε崺·ÎµåÄÁ¼³Æà |
¹Ì±¹°è ÈÀåǰȸ»ç RA Manager (Â÷-ºÎÀå±Þ)
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
8³â¡è |
ä¿ë½Ã |
07.28 |
|
|
(ÁÖ)±Û·Î¹úHRÆÄÆ®³Ê½º |
±¹³»Á¦¾à»ç °ü¸®¾à»ç Ãʺù
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
1³â¡è |
ä¿ë½Ã |
03.15 |
|
|
ÄÚ¸®¾ÆÇìµå |
À¯¸íÁ¦¾à»ç °³¹ß¾à»ç
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
3³â¡è |
ä¿ë½Ã |
09.01 |
|
|
JYpartners |
[[¾à»ç, ÇѾà»ç Çʼö]] CRA 2³â ÀÌ»ó °æ·ÂÀÚ OK
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
05.06 |
|
|
(ÁÖ)ÇÁ¶óÀ̸Ӹ®¿¡ÀÌÄ¡¾Ë |
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
3³â¡è |
ä¿ë½Ã |
08.26 |
|
|
³×¸ðÆÄÆ®³ÊÁîHRG |
¿Ü±¹°è Á¦¾àȸ»ç Medical advisor (ÀÌ»ç±Þ)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
5³â¡è |
ä¿ë½Ã |
10.29 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
»ç¾÷°³¹ß½ÇÆÀÀå(Business Development Team Leader)/±¹³»À¯
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
¾à»ç/ÇѾà»ç |
7³â¡è |
ä¿ë½Ã |
09.13 |
|